Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)

Recruiting N/A Interventional Study
Premature Infant Low Birthweight Infant
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 Days – 14 Days
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
188 (estimated)
Sponsor
Société des Produits Nestlé (SPN) · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose \[2'FL\] and lacto-N-neotetraose \[LNnT\], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting. A comparison with data collected retrospectively from a historical group at each si…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Written informed consent has been obtained from at least one parent (or other legally acceptable representative \[LAR\], if applicable) 2. Infant's parent(s)/LAR is of legal age of majority, has parental authority, must understand the consent form and other relevant study doc…
Contacts

Inez Sroda

+41217858259

Inez.Sroda@rd.nestle.com

CONTACT